Computational modeling of the bat HKU4 coronavirus 3CL(pro) inhibitors as a tool for the development of antivirals against the emerging Middle East respiratory syndrome (MERS) coronavirus

作者：Abuhammad Areej^*; Al Aqtash Rua'a A; Anson Brandon J; Mesecar Andrew D; Taha Mutasem O^*

来源：Journal of Molecular Recognition, 2017, 30(11): e2644.

DOI：10.1002/jmr.2644

• 3CL(pro) inhibitors
• coronavirus
• dbCICA
• MERS
• pharmacophore modeling

The Middle East respiratory syndrome coronavirus (MERS-CoV) is an emerging virus that poses a major challenge to clinical management.
The 3C-like protease (3CL(pro)) is essential for viral replication and thus represents a potential target for antiviral drug development. Presently, very few data are available on MERS-CoV 3CL(pro) inhibition by small molecules. We conducted extensive exploration of the pharmacophoric space of a recently identified set of peptidomimetic inhibitors of the bat HKU4-CoV 3CL(pro). HKU4-CoV 3CL(pro) shares high sequence identity (81%) with the MERS-CoV enzyme and thus represents a potential surrogate model for anti-MERS drug discovery. We used 2 well-established methods: Quantitative structure-activity relationship (QSAR)-guided modeling and docking-based comparative intermolecular contacts analysis. The established pharmacophore models highlight structural features needed for ligand recognition and revealed important binding-pocket regions involved in 3CL(pro)-ligand interactions. The best models were used as 3D queries to screen the National Cancer Institute database for novel nonpeptidomimetic 3CL(pro) inhibitors. The identified hits were tested for HKU4-CoV and MERS-CoV 3CL(pro) inhibition. Two hits, which share the phenylsulfonamide fragment, showed moderate inhibitory activity against the MERS-CoV 3CL(pro) and represent a potential starting point for the development of novel anti-MERS agents. To the best of our knowledge, this is the first pharmacophore modeling study supported by in vitro validation on the MERS-CoV 3CL(pro).
Highlights:
MERS-CoV is an emerging virus that is closely related to the bat HKU4-CoV.
3CL(pro) is a potential drug target for coronavirus infection.
HKU4-CoV 3CL(pro) is a useful surrogate model for the identification of MERS-CoV 3CL(pro) enzyme inhibitors.
dbCICA is a very robust modeling method for hit identification.
The phenylsulfonamide scaffold represents a potential starting point for MERS coronavirus 3CL(pro) inhibitors development.

• 出版日期2017-11